Literature DB >> 11774803

Diabetes in Bolivia.

A Barceló1, M C Daroca, R Ribera, E Duarte, A Zapata, M Vohra.   

Abstract

OBJECTIVE: To measure the prevalence of diabetes mellitus (DM), hypertension, obesity, and related risk factors in major cities in Bolivia.
METHODS: A population-based survey was conducted in four Bolivian cities: La Paz, El Alto, Santa Cruz, and Cochabamba. The total sample size was chosen to be 2,948 persons. The overall response rate was 86%, with the rate varying somewhat among the four cities. DM was diagnosed through an oral glucose tolerance test (OGTT) 2 hours after an overload of 75 grams of glucose, using World Health Organization criteria.
RESULTS: The overall prevalence of DM in the four urban areas combined was 7.2% (95% confidence interval (CI): 6.2%-8.3%) and of impaired glucose tolerance (IGT) was 7.8%. A total of 73.1% (95% CI: 65.0%-81.0%) of those previously diagnosed with DM and 73.7% (95% CI: 61.0%-86.4%) of newly diagnosed cases were overweight, according to measurements of body mass index. Hypertension was found in 36.5% (95% CI: 27.6%-45.5%) of known diabetics and in 36.6% (95% CI: 23.0%-50.1%) of newly diagnosed cases, compared to only 15.9% (95% CI: 14.3%-17.5%) among people without DM. The disease was most common among older persons and those with little education.
CONCLUSIONS: Diabetes is a genuine public health problem in Bolivia. Further, the high prevalence of IGT that was found suggests that diabetes prevalence will increase in the near future in the country unless prevention strategies are implemented.

Entities:  

Mesh:

Year:  2001        PMID: 11774803     DOI: 10.1590/s1020-49892001001100004

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  6 in total

1.  Social patterning of chronic disease risk factors in a Latin American city.

Authors:  Nancy L Fleischer; Ana V Diez Roux; Marcio Alazraqui; Hugo Spinelli
Journal:  J Urban Health       Date:  2008-10-02       Impact factor: 3.671

2.  Prevalence of diabetes and intermediate hyperglycemia among adults from the first multinational study of noncommunicable diseases in six Central American countries: the Central America Diabetes Initiative (CAMDI).

Authors:  Alberto Barcelo; Edward W Gregg; Robert B Gerzoff; Roy Wong; Enrique Perez Flores; Manuel Ramirez-Zea; Elizabeth Cafiero; Lesbia Altamirano; Melanie Ascencio Rivera; Gerardo de Cosio; Martha Dinorah de Maza; Roberto del Aguila; Englebert Emanuel; Enrique Gil; Ethan Gough; Valerie Jenkins; Patrícia Orellana; Ruben Palma; Ruben Palomo; Martha Pastora; Rodolfo Peña; Elia Pineda; Bismark Rodriguez; Luis Tacsan; Loraine Thompson; Lucy Villagra
Journal:  Diabetes Care       Date:  2012-02-08       Impact factor: 19.112

Review 3.  From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America.

Authors:  M Larissa Avilés-Santa; Uriyoán Colón-Ramos; Nangel M Lindberg; Josiemer Mattei; Francisco J Pasquel; Cynthia M Pérez
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-10       Impact factor: 5.555

Review 4.  Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent.

Authors:  M Larissa Avilés-Santa; Alberto Monroig-Rivera; Alvin Soto-Soto; Nangel M Lindberg
Journal:  Curr Diab Rep       Date:  2020-10-10       Impact factor: 4.810

5.  Health disparities from economic burden of diabetes in middle-income countries: evidence from México.

Authors:  Armando Arredondo; Gabriela Reyes
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

6.  Geographical variation in the progression of type 2 diabetes in Peru: The CRONICAS Cohort Study.

Authors:  Antonio Bernabé-Ortiz; Rodrigo M Carrillo-Larco; Robert H Gilman; Catherine H Miele; William Checkley; Jonathan C Wells; Liam Smeeth; J Jaime Miranda
Journal:  Diabetes Res Clin Pract       Date:  2016-09-21       Impact factor: 5.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.